PhysioCue Inc.

PhysioCue is a biotechnology and healthcare startup founded in 2013, with a focus on developing non-invasive medical devices for hypertension and migraine relief. The company's products have undergone clinical trials and have demonstrated efficacy in lowering high blood pressure and alleviating migraine pain. PhysioCue's non-invasive devices utilize controlled cold therapy to activate the carotid artery baroreceptor reflex, offering a safe and user-friendly alternative to pharmaceuticals and surgical options. These solutions are designed to be free from the side effects commonly associated with anti-hypertensive medications. Additionally, the company is working on a wearable mobile health device to further expand its product portfolio. PhysioCue's recent milestone includes a Seed Round investment in 18 March 2019 led by AQAL Group. This investment signifies confidence in PhysioCue's innovative approach to addressing critical healthcare needs and its potential for positive impact in the biotechnology and healthcare industries. With its unique non-invasive therapies and focus on clinical validation, PhysioCue has positioned itself as an intriguing prospect for potential venture capital investment, offering an opportunity to support groundbreaking solutions in the medical field with promising market potential.